Biogen Idec takes option to MAKScientific MS program

[MSUK]

MAKScientific, LLC, a privately held company focused on the discovery of novel therapeutics modulating cannabinoid pathways, today announced that it has entered into an exclusive, worldwide option and collaboration agreement with Biogen Idec to develop and commercialise drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.

Under the agreement, Biogen Idec will receive an option for an exclusive license to select discovery-stage MAKScientific drug candidates for all indications worldwide. Upon Biogen Idec's exercise of the option, MAKScientific will be eligible to receive an exercise fee of up to $3 million and up to an additional $31 million in milestone payments associated with the clinical development of the drug candidates. In addition, MAKScientific will be eligible to receive royalties on net sales worldwide. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2479

[Leonard]

interesting, they are going down the path of receptor health/functioning.
and interesting to see that lipids play their role here too..

http://en.wikipedia.org/wiki/Cannabinoid_receptor

still, I remain convinced that a narrow neurological approach is not the right way.
where the problem really originates in the gut and that it precisely there where 'they' should start..